What is Mazdutide? An Oxyntomodulin-Derived Dual Agonist
Mazdutide (development codes IBI362 and LY3305677) is a synthetic dual-receptor research peptide engineered from the oxyntomodulin backbone — the natural human peptide that endogenously engages both the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Where survodutide reaches the same dual-receptor pharmacology through a separately engineered chemistry, mazdutide takes the more biomimetic approach: optimize the structure that nature already evolved for dual-receptor agonism.
This article is a research-context overview of mazdutide, with mechanism, structural background, preclinical findings, and CoA considerations. Mazdutide is supplied for in vitro and animal-research applications only.
Reference identifiers
- CAS Registry Number: 2410796-79-9
- Development codes: IBI362, LY3305677
- Sequence length: 39 amino acids (oxyntomodulin-derived backbone)
- Molecular weight: ~4814 g/mol (approximate; varies by salt form)
- Form supplied: Lyophilized white powder
- Originator: Innovent Biologics, in licensing partnership with Eli Lilly
The CoA should report HPLC purity ≥99.0% with chromatogram visible, mass spectrum confirmation within ±0.5 Da, net peptide content, and lot number traceability. Any reputable research-supply vendor should publish the CoA per lot; verify that the lot number on the vial resolves to a downloadable PDF before use.
The oxyntomodulin connection
To understand mazdutide, it helps to understand its parent peptide. Oxyntomodulin is a 37-amino-acid peptide produced by enteroendocrine L-cells in the intestinal mucosa, co-secreted with GLP-1 from the same precursor (proglucagon) in response to nutrient intake. Unlike GLP-1, which engages only GLP-1R, oxyntomodulin engages both GLP-1R and GCGR with nanomolar affinity at both.
This is the natural template for GLP-1/glucagon dual agonism. Oxyntomodulin signals from the gut to the islet (via GLP-1R) and to the liver (via GCGR), producing integrated metabolic effects that include glucose-dependent insulin secretion, suppressed gastric emptying, increased energy expenditure, and modulation of hepatic glucose output. The dual-receptor pharmacology is not engineered — it is endogenous.
The pharmacokinetic liability of endogenous oxyntomodulin is the short circulating half-life (DPP-4-mediated degradation within minutes). The engineering challenge for a long-acting research analog is to extend the half-life while preserving the dual-receptor binding profile of the parent peptide.
Mazdutide design
Mazdutide solves the half-life problem through:
-
Substitutions at the DPP-4 cleavage site to block proteolytic degradation
-
C-terminal sequence extensions to enhance receptor binding
-
A fatty-acid modification at a lysine residue, providing albumin binding and extended circulating half-life
The result is a 39-amino-acid peptide retaining oxyntomodulin-like dual GLP-1R / GCGR agonism with a circulating half-life suitable for once-weekly research administration in animal-model designs.
Receptor pharmacology
Mazdutide engages both target receptors with nanomolar affinity:
– GLP-1R — drives glucose-dependent insulin secretion, α-cell glucagon suppression, delayed gastric emptying, and central satiety signaling
– GCGR — drives increased energy expenditure, modulation of hepatic lipid metabolism, and bile acid metabolism effects
The specific GLP-1R : GCGR activity ratio of mazdutide is reported to favor GLP-1R modestly, distinguishing it pharmacologically from survodutide (the alternative GLP-1/GCGR dual agonist), which is reported to have a different receptor activity ratio. This pharmacological distinction is relevant for research designs that want to isolate the contribution of relative receptor activity within the dual-agonist class.
For the broader catalog context — and for comparative discussion of survodutide — see the what is survodutide overview.
Preclinical animal-study findings
The published mazdutide preclinical literature reports:
– Dose-dependent reductions in food intake in DIO mouse and rat models
– Sustained body weight reduction over multi-week dosing protocols
– Improved glucose tolerance under sustained dosing
– Reduced hepatic triglyceride content in animal models of fatty liver disease
– Modulation of bile acid metabolism markers
– Improved insulin sensitivity in obese-diabetic rodent models
The hepatic-lipid findings are characteristic of the GLP-1/GCGR dual-agonist class — the glucagon-receptor arm engages hepatic biology in ways that GLP-1 monoagonists do not. For research designs probing MASLD/MASH preclinical pharmacology, mazdutide and survodutide together provide a comparator pair within the dual-agonist class.
None of these findings constitute evidence of safety or efficacy in humans.
How mazdutide differs from survodutide and tirzepatide
| Feature | Mazdutide | Survodutide | Tirzepatide |
|---|---|---|---|
| Receptors | GLP-1R + GCGR | GLP-1R + GCGR | GLP-1R + GIPR |
| Parent backbone | Oxyntomodulin | Engineered | GIP-derived |
| Sequence length | 39 aa | 29 aa | 39 aa |
| GLP-1R:secondary ratio | Favors GLP-1R | Different ratio | Balanced |
– GLP-1 + GIP — tirzepatide
– GLP-1 + glucagon — mazdutide, survodutide
For research designs probing the contribution of GIP vs. glucagon receptor activity, the three compounds in parallel arms provide a clean experimental framework.
CoA verification
Standard CoA verification points for mazdutide:
– HPLC purity ≥99.0% with chromatogram visible
– Mass spectrum confirming expected mass within ±0.5 Da
– Sequence confirmation — the 39-residue oxyntomodulin-derived backbone with engineered substitutions and the fatty-acid modification
– Net peptide content with counterion identified
– Lot number matching vial
The fatty-acid modification check is essential. Without the albumin-binding moiety, the underlying peptide has a circulating half-life inadequate for the intended research applications.
Storage
Mazdutide is supplied lyophilized. Pre-reconstitution: 2–8°C, dry, away from light; -20°C for archival storage. Post-reconstitution: 2–8°C in standard multi-dose diluent, use within ~28 days. Reconstitute by adding diluent slowly to vial wall; gentle inversion only, no shaking.
Summary
Mazdutide is a 39-amino-acid oxyntomodulin-derived GLP-1/glucagon dual-receptor agonist research peptide. It preserves the natural dual-receptor pharmacology of the parent oxyntomodulin while engineering in extended circulating half-life through DPP-4-resistant substitutions and a fatty-acid albumin-binding modification. Preclinical literature reports body weight reduction, improved glucose tolerance, and hepatic lipid metabolism effects in standard metabolic-model readouts. It complements survodutide as a parallel GLP-1/GCGR dual-agonist research probe with a distinct chemistry and receptor activity ratio.
Research Use Only. Not for use in or on humans or animals. Not a food, drug, cosmetic, or supplement.